Loading patent…
AssigneesThe Cleveland Clinic Foundation, The Regents of the University of California
InventorsRobert H. Silverman, Eric A. Klein, Graham Casey, Joseph DeRisi, Don Ganem
Estimating the term…
The present invention provides for isolated nucleic acid sequences encoding viruses; isolated polypeptides comprising amino acid sequences of the virus; vectors comprising the viral nucleic acid sequences; cells comprising the vectors; antibodies and antigen binding fragments thereof which have binding specificity for the virus; methods of detecting or screening for the virus (e.g., in an individual); methods of identifying agents that inhibit the virus; methods of inducing an immune response to the virus; methods of treating disease associated with the presence of XMRV in an individual (e.g., cancer such as prostate cancer); methods of detecting asymptomatic cancer (e.g., prostate cancer); methods of identifying an individual at risk for developing cancer (e.g., prostate cancer); and kits for detecting the virus.
An isolated XMRV present in a prostate tumor of an individual.
An isolated virus comprising a nucleic acid sequence having at least 94% identity to SEQ ID No:
(canceled)
(canceled)
An isolated virus comprising SEQ ID No:
An isolated polypeptide comprising an amino acid sequence having at least 97% similarity to SEQ ID No:
(canceled)
(canceled)
A method of detecting XMRV in a sample comprising:
A method of detecting XMRV in a sample comprising:
A method of identifying an agent that inhibits an XMRV comprising:
A method of inducing an immune response to an XMRV in an individual in need thereof, comprising administering to the individual an effective amount of an agent which induces an immune response to the XMRV in the individual upon administration.
A method of treating prostate cancer in an individual wherein XMRV is present in the prostate of the individual, comprising administering to the individual an effective amount of an agent that inhibits XMRV.
A method of detecting asymptomatic (early stage) prostate cancer in an individual wherein XMRV is present in the prostate of the individual, comprising detecting the presence of an XMRV in the individual, wherein the presence of XMRV in the individual is indicative of early stage prostate cancer in the individual.
A method of identifying an individual at risk for developing prostate cancer, comprising determining whether an XMRV is present in the individual, wherein if XMRV is present in the individual then the individual is at risk for developing prostate cancer.
A kit for detecting the presence of XMRV in a sample comprising a labeled moiety that detects XMRV in a sample.
Dependencies are inferred from the claim text.